Sökning: onr:"swepub:oai:DiVA.org:uu-468640" >
Long-term tolerabil...
-
Flygt, HjalmarUppsala universitet,Hematologi
(författare)
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
- Artikel/kapitelEngelska2021
Förlag, utgivningsår, omfång ...
-
2021-08-31
-
John Wiley & Sons,2021
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-468640
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-468640URI
-
https://doi.org/10.1111/ejh.13699DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:147513672URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Title in Web of Science: Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
-
ObjectivesTreatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of tyrosine kinase inhibitors (TKI) and other drugs. Interferon-α in addition to TKI has shown promising efficacy but with dose-dependent toxicity and discontinuations. NordCML007 was initiated to study the efficacy and safety of low dose pegylated IFN-α (PegIFN-α) in combination with dasatinib (DAS) in CML-CP.MethodsForty patients with newly diagnosed CML-CP were given DAS upfront. After month 3 (M3) 15 μg/wk of PegIFN-α was added and increased to 25 μg/wk from M7 until M15. DAS treatment was continued and adverse events and BCR-ABL1 qRT-PCR values were reported yearly after M24. Results from M1 to M18 have previously been published, and here we present long-term data.ResultsAfter 5 years of follow-up, there were no suspected unexpected serious adverse reactions, no increase in serosal effusions, no disease progressions and no CML-related deaths. Rates of MR3.0 (MMR), MR4.0 and MR4.5 were 84.6%, 64.1% and 51.3% respectively at M60, and 95% of patients reached MMR at some point during the study.ConclusionInitial addition of PegIFN-α to DAS shows good long-term efficacy without increased toxicity.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Söderlund, StinaUppsala universitet,Hematologi(Swepub:uu)stiso746
(författare)
-
Stentoft, JesperAarhus Univ Hosp, Dept Hematol, Aarhus, Denmark.
(författare)
-
Richter, JohanSkane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.
(författare)
-
Koskenvesa, PerttuUniv Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Hematol Res Unit Helsinki, Helsinki, Finland.;Univ Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland.
(författare)
-
Mustjoki, SatuUniv Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Hematol Res Unit Helsinki, Helsinki, Finland.;Univ Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Translat Immunol Res Program, Helsinki, Finland.;Univ Helsinki, Dept Clin Chem & Hematol, Helsinki, Finland.
(författare)
-
Majeed, WaleedStavanger Univ Hosp, Dept Hematooncol, Stavanger, Norway.
(författare)
-
Lübking, AnnaSkane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.
(författare)
-
Dreimane, ArtaLinköping Univ Hosp, Dept Hematol, Linköping, Sweden.
(författare)
-
Markevärn, BeritUmeå Univ Hosp, Dept Hematol, Umeå, Sweden.
(författare)
-
Stenke, LeifKarolinska Institutet
(författare)
-
Myhr Eriksson, KristinaSunderby Hosp, Dept Internal Med & Hematol, Luleå, Sweden.
(författare)
-
Gjertsen, Bjørn ToreHaukeland Hosp, Hematol Sect, Dept Internal Med, Bergen, Norway.
(författare)
-
Gedde-Dahl, TobiasNatl Hosp Norway, Oslo Univ Hosp, Dept Hematol, Oslo, Norway.
(författare)
-
Dimitrijevic, AndrejaOdense Univ Hosp, Dept Hematol, Odense, Denmark.
(författare)
-
Udby, LeneZealand Univ Hosp, Dept Hematol, Roskilde, Denmark.
(författare)
-
Olsson-Strömberg, UllaUppsala universitet,Hematologi(Swepub:uu)ulols170
(författare)
-
Hjorth-Hansen, HenrikSt Olavs Hosp Trondheim, Dept Hematol, Trondheim, Norway.;Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway.
(författare)
-
Uppsala universitetHematologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Journal of Haematology: John Wiley & Sons107:6, s. 617-6230902-44411600-0609
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Flygt, Hjalmar
-
Söderlund, Stina
-
Stentoft, Jesper
-
Richter, Johan
-
Koskenvesa, Pert ...
-
Mustjoki, Satu
-
visa fler...
-
Majeed, Waleed
-
Lübking, Anna
-
Dreimane, Arta
-
Markevärn, Berit
-
Stenke, Leif
-
Myhr Eriksson, K ...
-
Gjertsen, Bjørn ...
-
Gedde-Dahl, Tobi ...
-
Dimitrijevic, An ...
-
Udby, Lene
-
Olsson-Strömberg ...
-
Hjorth-Hansen, H ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet